Top

European Archives of Oto-Rhino-Laryngology

Published in:

01-03-2020 | Epistaxis | Rhinology

Patient-recorded benefit from nasal closure in a Danish cohort of patients with hereditary haemorrhagic telangiectasia

Authors: Jonas Hjelm Andersen, Anette Drøhse Kjeldsen

Published in: European Archives of Oto-Rhino-Laryngology | Issue 3/2020

Abstract

Background

Nasal closure, also known as the modified Young’s procedure was introduced in Denmark in 2008, as a surgical solution to severe epistaxis in patients with hereditary haemorrhagic telangiectasia (HHT). The objective of this study was to report the overall satisfaction of the procedure from a patient’s point of view as well as the occurrence of complications.

Methods

All the HHT patients who underwent nasal closure from 2008 to 2018 were included in the study. The patients were evaluated for postoperative complications and subjective outcome using Glasgow Benefit Inventory (GBI).

Results

Ten patients were included in the study and were observed for a mean of 64 months. None of the patients was completely free of complications, and reversal was requested in a single case. Haemoglobin levels rose with an average of 2.8 g/dl. The average GBI score after surgery was 38.05. Nine of ten patients would recommend nasal closure to fellow HHT patients.

Conclusion

Nasal closure is highly recommended among patients, but due to the rate of postoperative complications, the procedure should be reserved for a carefully selected group of HHT patients.

Available only for authorised users

Shovlin CL, Guttmacher AE, Buscarini E et al (2000) Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu–Osler–Weber Syndrome). Am J Med Genet 67:66–67CrossRef

Kritharis A, Al-samkari H, Kuter DJ et al (2018) Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist’s perspective. Haematologica. https://doi.org/10.3324/haematol.2018.193003 CrossRefPubMedPubMedCentral

Dheyauldeen S, Abdelnoor M, Bachmann-Harildstad G (2011) The natural history of epistaxis in patients with hereditary hemorrhagic telangiectasia in the Norwegian population: a cross-sectional study. Am J Rhinol Allergy. 25(4):214–218. https://doi.org/10.2500/ajra.2011.25.3616 CrossRefPubMed

Shovlin CL, Buscarini E, Kjeldsen AD, Mager HJ, Sabba C, Droege F (2018) European Reference Network For Rare Vascular Diseases (VASCERN) outcome measures for hereditary haemorrhagic telangiectasia (HHT). Orphanet J Rare Dis 13(1):136. https://doi.org/10.1186/s13023-018-0850-2 CrossRefPubMedPubMedCentral

Jørgensen G, Lange B, Wanscher JH, Kjeldsen AD (2011) Efficiency of laser treatment in patients with hereditary hemorrhagic telangiectasia. Eur Arch Oto-Rhino-Laryngol 268(12):1765–1770. https://doi.org/10.1007/s00405-011-1677-9 CrossRef

Harvey RJ, Kanagalingam J, Lund VJ (2008) The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol. https://doi.org/10.2500/ajr.2008.22.3145 CrossRefPubMed

Fialla TRAD, Kjeldsen A (2019) Does severe bleeding in HHT patients respond to intravenous bevacuzimab. Review of the literature and case series. Rhinol J. https://doi.org/10.4193/Rhino16.054 CrossRef

Young A (1967) Closure of the nostrils in atrophic rhinitis. Indian J Otolaryngol. https://doi.org/10.1007/BF03047450 CrossRef

Lund VJ, Howard DJ (1997) Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 111(1):30–33. https://doi.org/10.1017/s0022215100136369 CrossRefPubMed

10.

Robinson K, Gatehouse S, Browning GG (1996) Measuring patient benefit from otorhinolaryngological surgery and therapy. Ann Otol Rhinol Laryngol. https://doi.org/10.1177/000348949610500601 CrossRefPubMed

11.

Richer SL, Geisthoff UW, Livada N et al (2012) The Young’s procedure for severe epistaxis from hereditary hemorrhagic telangiectasia. Am J Rhinol Allergy 26(5):401–402. https://doi.org/10.2500/ajra.2012.26.3809 CrossRefPubMed

12.

Lund VJ, Darby Y, Rimmer J, Amin M, Husain S (2018) Nasal closure for severe hereditary haemorrhagic telangiectasia in 100 patients. The Lund modification of the Young’s procedure: a 22-year experience. Rhinol J. 55(2):135–141. https://doi.org/10.4193/rhin16.315 CrossRef

13.

Hendry J, Chin A, Swan IRC, Akeroyd MA, Browning GG (2016) The Glasgow Benefit Inventory: a systematic review of the use and value of an otorhinolaryngological generic patient-recorded outcome measure. Clin Otolaryngol. 41(3):259–275. https://doi.org/10.1111/coa.12518 CrossRefPubMedPubMedCentral

14.

Gossage JR (2018) The current role of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia-related bleeding. Mayo Clin Proc 93(2):130–132. https://doi.org/10.1016/j.mayocp.2017.12.019 CrossRefPubMed

15.

Iyer VN, Apala DR, Pannu BS et al (2018) Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding. Mayo Clin Proc. https://doi.org/10.1016/j.mayocp.2017.11.013 CrossRefPubMed

16.

Aagaard KS, Kjeldsen AD, Tørring PM, Green A (2018) Comorbidity among HHT patients and their controls in a 20 years follow-up period. Orphanet J Rare Dis. 13(1):1–9. https://doi.org/10.1186/s13023-018-0962-8 CrossRef

17.

Sexton A, Gargan B, Taylor J, Bogwitz M, Winship I (2019) Living with hereditary haemorrhagic telangiectasia: stigma, coping with unpredictable symptoms, and self-advocacy. Psychol Heal. https://doi.org/10.1080/08870446.2019.1583341 CrossRef

18.

Geirdal AØ, Dheyauldeen S, Bachmann-Harildstad G, Heimdal K (2012) Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: A population based study. Am J Med Genet Part A 158A(6):1269–1278. https://doi.org/10.1002/ajmg.a.35309 CrossRefPubMed

19.

Thomson RS, Molin NL, Whitehead KJ et al (2018) The effects of nasal closure on quality of life in patients with hereditary hemorrhagic telangiectasia. Laryngosc Investig Otolaryngol. 3(3):178–181. https://doi.org/10.1002/lio2.157 CrossRef

20.

Hitchings AE, Lennox PA, Lund VJ, Howard DJ (2005) The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. Am J Rhinol 19(1):75–78. https://www.ncbi.nlm.nih.gov/pubmed/15794079.CrossRef

Title: Patient-recorded benefit from nasal closure in a Danish cohort of patients with hereditary haemorrhagic telangiectasia
Authors: Jonas Hjelm Andersen
Anette Drøhse Kjeldsen
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Epistaxis
Laser
Hereditary Hemorrhagic Telangiectasia
Published in: European Archives of Oto-Rhino-Laryngology / Issue 3/2020
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-019-05758-1

At a glance: The STEP trials

Springer Medicine

Patient-recorded benefit from nasal closure in a Danish cohort of patients with hereditary haemorrhagic telangiectasia

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2020

Comparison of two routes in nasal passage for transnasale flexible fiberoptic laryngoscopy

Feasibility of 3D printed salivary duct models for sialendoscopic skills training: preliminary report

Immunohistochemical expression of TFIIH and XPF in oral tongue squamous cell carcinoma

Prognostic factors and risk factors for development and recurrence of sinonasal papillomas: potential role of different HPV subtypes

Clinical difference between benign and malignant tumors of the hard palate

Narrow Band Imaging for lingual tonsil hypertrophy and inflammation, in laryngo-pharyngeal reflux disease